One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK
Peck Lin Lip,1 Huzaifa Malick,1 Kenan Damer,1 Samer Elsherbiny,1 Kanupriya M Darrad,1 Bushra Mushtaq,1 Arijit Mitra,1 Panagiota Stavrou,1 Yit Yang1,2 1Birmingham and Midland Eye Centre, City Hospital, 2School of Health and Life Sciences, Aston University, Birmingham, UK Background: The purpose of...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cfbd5243eeaf4009abdea30d4290c4e9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cfbd5243eeaf4009abdea30d4290c4e9 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cfbd5243eeaf4009abdea30d4290c4e92021-12-02T03:41:33ZOne-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK1177-5483https://doaj.org/article/cfbd5243eeaf4009abdea30d4290c4e92015-09-01T00:00:00Zhttps://www.dovepress.com/one-year-outcome-of-bevacizumab-therapy-for-chronic-macular-edema-in-c-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Peck Lin Lip,1 Huzaifa Malick,1 Kenan Damer,1 Samer Elsherbiny,1 Kanupriya M Darrad,1 Bushra Mushtaq,1 Arijit Mitra,1 Panagiota Stavrou,1 Yit Yang1,2 1Birmingham and Midland Eye Centre, City Hospital, 2School of Health and Life Sciences, Aston University, Birmingham, UK Background: The purpose of this study was to investigate the 12-month outcome of macular edema secondary to both chronic and new central and branch retinal vein occlusions treated with intravitreal bevacizumab in the real-life clinical setting in the UK.Methods: Retrospective case notes analysis of consecutive patients with retinal vein occlusions treated with bevacizumab in 2010 to 2012. Outcome measures were visual acuity (measured with Snellen, converted into logMAR [logarithm of the minimum angle of resolution] for statistical calculation) and central retinal thickness at baseline, 4 weeks post-loading phase, and at 1 year.Results: There were 56 and 100 patients with central and branch retinal vein occlusions, respectively, of whom 62% had chronic edema and received prior therapies and another 32% required additional laser treatments post-baseline bevacizumab. Baseline median visual acuity was 0.78 (interquartile range [IQR] 0.48–1.22) in the central group and 0.6 (IQR 0.3–0.78) in the branch group. In both groups, visual improvement was statistically significant from baseline compared to post-loading (P<0.001 and P=0.03, respectively), but was not significant by month 12 (P=0.058 and P=0.166, respectively); 30% improved by at least three lines and 44% improved by at least one line by month 12. Baseline median central retinal thickness was 449 µm (IQR 388–553) in the central group and 441 µm (IQR 357–501) in the branch group. However, the mean reduction in thickness was statistically significant at post-loading (P<0.001) and at the 12-month time point (P<0.001) for both groups. The average number of injections in 1 year was 4.2 in the central group and 3.3 in the branch group.Conclusion: Our large real-world cohort results indicate that bevacizumab introduced to patients with either new or chronic edema due to retinal vein occlusion can result in resolution of edema and stabilization of vision in the first year. Keywords: chronic, risk factors, laser, loading dose, subretinal fluidLip PLMalick HDamer KElsherbiny SDarrad KMMushtaq BMitra AStavrou PYang YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 1779-1784 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Lip PL Malick H Damer K Elsherbiny S Darrad KM Mushtaq B Mitra A Stavrou P Yang Y One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| description |
Peck Lin Lip,1 Huzaifa Malick,1 Kenan Damer,1 Samer Elsherbiny,1 Kanupriya M Darrad,1 Bushra Mushtaq,1 Arijit Mitra,1 Panagiota Stavrou,1 Yit Yang1,2 1Birmingham and Midland Eye Centre, City Hospital, 2School of Health and Life Sciences, Aston University, Birmingham, UK Background: The purpose of this study was to investigate the 12-month outcome of macular edema secondary to both chronic and new central and branch retinal vein occlusions treated with intravitreal bevacizumab in the real-life clinical setting in the UK.Methods: Retrospective case notes analysis of consecutive patients with retinal vein occlusions treated with bevacizumab in 2010 to 2012. Outcome measures were visual acuity (measured with Snellen, converted into logMAR [logarithm of the minimum angle of resolution] for statistical calculation) and central retinal thickness at baseline, 4 weeks post-loading phase, and at 1 year.Results: There were 56 and 100 patients with central and branch retinal vein occlusions, respectively, of whom 62% had chronic edema and received prior therapies and another 32% required additional laser treatments post-baseline bevacizumab. Baseline median visual acuity was 0.78 (interquartile range [IQR] 0.48–1.22) in the central group and 0.6 (IQR 0.3–0.78) in the branch group. In both groups, visual improvement was statistically significant from baseline compared to post-loading (P<0.001 and P=0.03, respectively), but was not significant by month 12 (P=0.058 and P=0.166, respectively); 30% improved by at least three lines and 44% improved by at least one line by month 12. Baseline median central retinal thickness was 449 µm (IQR 388–553) in the central group and 441 µm (IQR 357–501) in the branch group. However, the mean reduction in thickness was statistically significant at post-loading (P<0.001) and at the 12-month time point (P<0.001) for both groups. The average number of injections in 1 year was 4.2 in the central group and 3.3 in the branch group.Conclusion: Our large real-world cohort results indicate that bevacizumab introduced to patients with either new or chronic edema due to retinal vein occlusion can result in resolution of edema and stabilization of vision in the first year. Keywords: chronic, risk factors, laser, loading dose, subretinal fluid |
| format |
article |
| author |
Lip PL Malick H Damer K Elsherbiny S Darrad KM Mushtaq B Mitra A Stavrou P Yang Y |
| author_facet |
Lip PL Malick H Damer K Elsherbiny S Darrad KM Mushtaq B Mitra A Stavrou P Yang Y |
| author_sort |
Lip PL |
| title |
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| title_short |
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| title_full |
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| title_fullStr |
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| title_full_unstemmed |
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK |
| title_sort |
one-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the uk |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/cfbd5243eeaf4009abdea30d4290c4e9 |
| work_keys_str_mv |
AT lippl oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT malickh oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT damerk oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT elsherbinys oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT darradkm oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT mushtaqb oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT mitraa oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT stavroup oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk AT yangy oneyearoutcomeofbevacizumabtherapyforchronicmacularedemaincentralandbranchretinalveinocclusionsinrealworldclinicalpracticeintheuk |
| _version_ |
1718401699816669184 |